Skip to content
OpenCapital
Get started

Ginkgo Bioworks DNA Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
——
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
——
Guardant Health logo
Guardant HealthGH
——

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Ginkgo Bioworks (DNA) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $15.38 in Q1 2026.
How has Ginkgo Bioworks's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Ginkgo Bioworks's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price decreased by 34.8% year-over-year, from $23.58 to $15.38.
What is the long-term trend for Ginkgo Bioworks's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 5 years (2020 to 2025), Ginkgo Bioworks's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a 277.7% compound annual growth rate (CAGR), from $0.02 to $15.38.